APE1与P-gp在晚期非小细胞肺癌中的表达及其临床意义

Study on Expression and Clinical Significance of APE1 and P-gp in Advanced Non-Small Cell Lung Cancer

目的探讨脱嘌呤脱嘧啶核酸内切酶1(APE1/ref-1)和P糖蛋白(P-gp)在晚期非小细胞肺癌(NSCLC)中的表达及其临床意义。方法采用免疫组化方法,检测晚期NSCLC患者肿瘤标本中的APE1和P-gp的表达,探讨APE1和P-gp与晚期NSCLC患者化疗疗效的相关性。结果58例非小细胞肺癌中45例APE1呈高表达,其表达与患者年龄、性别、肿瘤病理类型及临床分期无关;P-gp高表达28例,腺癌中其高表达率高于鳞癌,但与患者年龄、性别及临床分期无关。APE1表达与P-gp表达呈正相关。APE1高表达组、APE1低表达组、P-gp高表达组及P-gp低表达组化疗有效率依次为26.7%、61.5%、21.4%和46.7%,差异有统计学意义。结论APE1和P-gp表达与晚期NSCLC化疗疗效密切相关,对晚期NSCLC耐药机制的研究及其化疗疗效的评价具有重要意义。

Objective To investigate the expression and clinical significance of Apurinic/Apyrimidinic Endonuclease 1 and P-gp in advanced non-small cell lung cancer. Methods Fifty-eight cases with untreated stage ⅢB or Ⅳ NSCLC were reviewed. The expression of APE1 and P-gp was examined by immunohistochemical method in the patients＇ tumor samples. The correlation of the expression of APE1 and P-gp with response to chemotherapy was evaluated. Results Forty-five and twenty-eight of 58 NSCLC was determined to demonstrate over-expression of APE1 and P-gp, respectively. APE1 had no correlation with age ,gender, pathological type and clinical stage of the patients. There was significant difference in P-gp over-expression between squamous cell carcinoma and adenocarcinoma. P-gp had no correlation with age, gender, and clinical stage of the patients. Spearman analysis showed that there was a positive correlation between the expression of APE1 and P-gp. The response rates in over-expression/lowexpression of APE1 and P-gp were 26.7% ,61.5% ,21.4% and 46.7%. Conclusion Examination of APE1 and P-gp in lung carcinoma tissues can assist in the judgment of effectiveness of chemotherapy and be helpful to study on the mechanism of drug resistance to chemotherapy in advanced NSCLC patients.